BioNTech (NASDAQ:BNTX) CEO Sells $1,656,820.00 in Stock

BioNTech SE Sponsored ADR (NASDAQ:BNTX) CEO Ugur Sahin sold 17,000 shares of the firm’s stock in a transaction that occurred on Thursday, October 1st. The shares were sold at an average price of $97.46, for a total transaction of $1,656,820.00. Following the completion of the transaction, the chief executive officer directly owned 197,209 shares of the company’s stock, valued at approximately $19,219,989.14. The trade was a 7.94% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Ugur Sahin also recently made the following trade(s):

• On Wednesday, September 30th, Ugur Sahin sold 32,000 shares of BioNTech stock. The stock was sold at an average price of $98.12, for a total transaction of $3,139,840.00.
• On Monday, September 28th, Ugur Sahin sold 34,000 shares of BioNTech stock. The stock was sold at an average price of $98.47, for a total transaction of $3,347,980.00.
• On Friday, September 25th, Ugur Sahin sold 27,000 shares of BioNTech stock. The stock was sold at an average price of $98.69, for a total transaction of $2,664,630.00.
• On Thursday, September 24th, Ugur Sahin sold 39,000 shares of BioNTech stock. The shares were sold at an average price of $98.99, for a total transaction of $3,860,610.00.
• On Wednesday, September 23rd, Ugur Sahin sold 30,000 shares of BioNTech stock. The stock was sold at an average price of $99.40, for a total transaction of $2,982,000.00.
• On Tuesday, September 22nd, Ugur Sahin sold 46,000 shares of BioNTech stock. The stock was sold at an average price of $100.72, for a total value of $4,633,120.00.
• On Monday, September 21st, Ugur Sahin sold 33,000 shares of BioNTech stock. The shares were sold at an average price of $97.81, for a total value of $3,227,730.00.
• On Friday, September 18th, Ugur Sahin sold 30,000 shares of BioNTech stock. The shares were sold at an average price of $96.22, for a total value of $2,886,600.00.
• On Thursday, September 17th, Ugur Sahin sold 34,000 shares of BioNTech stock. The stock was sold at an average price of $98.60, for a total value of $3,352,400.00.
• On Wednesday, September 16th, Ugur Sahin sold 15,000 shares of BioNTech stock. The stock was sold at an average price of $96.09, for a total value of $1,441,350.00.

BioNTech Price Performance

BNTX stock opened at $96.90 on Monday. The company has a debt-to-equity ratio of 0.01, a current ratio of 7.85 and a quick ratio of 7.80. The firm has a market capitalization of $24.50 billion, a P/E ratio of -12.38 and a beta of 1.25. The business’s 50-day moving average is $98.81 and its two-hundred day moving average is $95.04. BioNTech SE Sponsored ADR has a 1 year low of $79.52 and a 1 year high of $124.00.

BioNTech (NASDAQ:BNTX) last announced its quarterly earnings data on Tuesday, August 4th. The company reported ($2.53) EPS for the quarter, missing analysts’ consensus estimates of ($2.40) by ($0.13). The company had revenue of $122.31 million for the quarter, compared to analyst estimates of $180.18 million. BioNTech had a negative return on equity of 6.86% and a negative net margin of 63.54%.The business’s quarterly revenue was down 59.5% compared to the same quarter last year. During the same period in the prior year, the firm posted ($1.60) earnings per share. Analysts anticipate that BioNTech SE Sponsored ADR will post -6.37 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in the company. Integrated Wealth Concepts LLC acquired a new stake in shares of BioNTech in the second quarter valued at approximately $39,000. Caitong International Asset Management Co. Ltd raised its position in BioNTech by 1,012.0% in the 4th quarter. Caitong International Asset Management Co. Ltd now owns 556 shares of the company’s stock valued at $53,000 after purchasing an additional 506 shares during the last quarter. Vestcor Inc acquired a new stake in BioNTech during the 4th quarter worth $153,000. Rockefeller Capital Management L.P. grew its position in BioNTech by 328.6% during the 4th quarter. Rockefeller Capital Management L.P. now owns 1,856 shares of the company’s stock worth $177,000 after purchasing an additional 1,423 shares during the last quarter. Finally, Quantum Portfolio Management LLC acquired a new position in BioNTech in the first quarter valued at $203,000. Hedge funds and other institutional investors own 15.52% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of brokerages have recently weighed in on BNTX. Canaccord Genuity Group reduced their price objective on shares of BioNTech from $142.00 to $136.00 and set a “buy” rating on the stock in a report on Monday, August 31st. UBS Group reaffirmed a “buy” rating on shares of BioNTech in a report on Wednesday, September 16th. Citigroup dropped their price objective on BioNTech from $130.00 to $125.00 and set a “buy” rating on the stock in a report on Wednesday, August 5th. Morgan Stanley decreased their target price on BioNTech from $126.00 to $119.00 and set an “overweight” rating for the company in a research note on Wednesday, July 8th. Finally, Berenberg Bank set a $140.00 price target on BioNTech in a report on Wednesday, September 16th. One equities research analyst has rated the stock with a Strong Buy rating, twelve have given a Buy rating, five have assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, BioNTech presently has an average rating of “Moderate Buy” and an average target price of $126.00.

About BioNTech

BioNTech SE is a biotechnology company headquartered in Mainz, Germany, focused on developing therapies and vaccines for cancer and other serious diseases. The company’s research platform includes messenger RNA (mRNA), individualized cancer vaccines, immune-modulating therapies, cell therapies, and protein-based therapeutics.

BioNTech is best known for developing the Comirnaty COVID-19 vaccine in collaboration with Pfizer. Comirnaty uses mRNA technology to help stimulate an immune response against COVID-19 and has been distributed in markets around the world.